Crenigacestat, a selective NOTCH1 inhibitor, reduces intrahepatic cholangiocarcinoma progression by blocking VEGFA/DLL4/MMP13 axis

Serena Mancarella(Gastroenterology Hospital "Saverio de Bellis"), Gianluigi Giannelli(GTx (United States))

Cell Death and Differentiation

February 10, 2020

10.1038/s41418-020-0505-4

Cited by 68

Related Papers

Role of epithelial to mesenchymal transition in hepatocellular carcinoma

|Journal of Hepatology|2016|641

Targeting transforming growth factor (TGF)‐βRI inhibits activation of β1 integrin and blocks vascular invasion in hepatocellular carcinoma†

|Hepatology|2008|140

Hepatic stellate cells induce hepatocellular carcinoma cell resistance to sorafenib through the laminin‐332/α3 integrin axis recovery of focal adhesion kinase ubiquitination

|Hepatology|2016|102

Differential Inhibition of the TGF-β Signaling Pathway in HCC Cells Using the Small Molecule Inhibitor LY2157299 and the D10 Monoclonal Antibody against TGF-β Receptor Type II

|PLoS ONE|2013|94

Laminin-5 stimulates hepatocellular carcinoma growth through a different function of α6β4 and α3β1 integrins

|Hepatology|2007|71